Zosano Pharma is a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using its proprietary intracutaneous microneedle system (the System). Co.'s development activities are focused on its product candidate, Qtrypta (M207). Qtrypta (M207) is Co.'s proprietary formulation of zolmitriptan delivered utilizing its System. Zolmitriptan is one of a class of serotonin receptor agonists known as triptans and is used as an acute treatment for migraine. Qtrypta (M207) is designed for absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal tract. The ZSAN average annual return since 2015 is shown above.
The Average Annual Return on the ZSAN average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ZSAN average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ZSAN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|